Quote | Altamira Therapeutics Ltd. (NASDAQ:CYTO)
Last: | $1.62 |
---|---|
Change Percent: | 0.62% |
Open: | $1.61 |
Close: | $1.62 |
High: | $1.6651 |
Low: | $1.57 |
Volume: | 35,174 |
Last Trade Date Time: | 05/02/2024 03:00:00 am |
News | Altamira Therapeutics Ltd. (NASDAQ:CYTO)
Hamilton, Bermuda, May 01, 2024 (GLOBE NEWSWIRE) -- Continued expansion of IP portfolio related to RNA delivery Treatment of rheumatoid arthritis as one of the key therapeutic indications HAMILTON, BERMUDA / May 1, 2024 / Altamira Therapeutics Ltd. (“Altamira” or t...
2024-04-24 10:11:05 ET More on Altamira Therapeutics Altamira stock rallies 44% on Univercells mRNA collaboration Seeking Alpha’s Quant Rating on Altamira Therapeutics Financial information for Altamira Therapeutics Read the full article on Seeking A...
Message Board Posts | Altamira Therapeutics Ltd. (NASDAQ:CYTO)
Subject | By | Source | When |
---|---|---|---|
$CYTO new 52 week low | Monksdream | investorshub | 07/05/2023 5:07:30 PM |
$CYTO Long and strong lets hope im right | jchords | investorshub | 07/02/2023 11:20:40 PM |
$CYTO What do you make of this? | subslover | investorshub | 07/02/2023 4:18:32 PM |
$CYTO Price gaining last up | LowFloatLopes | investorshub | 06/30/2023 8:52:23 PM |
$CYTO just the news we needed | subslover | investorshub | 06/26/2023 7:02:45 AM |
News, Short Squeeze, Breakout and More Instantly...
Altamira Therapeutics Ltd. Company Name:
CYTO Stock Symbol:
NASDAQ Market:
Hamilton, Bermuda, May 01, 2024 (GLOBE NEWSWIRE) -- Continued expansion of IP portfolio related to RNA delivery Treatment of rheumatoid arthritis as one of the key therapeutic indications HAMILTON, BERMUDA / May 1, 2024 / Altamira Therapeutics Ltd. (“Altamira” or t...
Hamilton, Bermuda, April 24, 2024 (GLOBE NEWSWIRE) -- Detailed results from randomized controlled Bentrio® trial in seasonal allergic rhinitis published in Allergy journal Study met primary efficacy endpoint of improvement in nasal symptoms (p = 0.013) Corroborated ...
Hamilton, Bermuda, April 10, 2024 (GLOBE NEWSWIRE) -- Management to host conference call today, April 10, at 8.30 a.m. EDT RNA delivery business progressing with new collaborations, potential new applications Partnering of legacy assets underway as Company transitions to f...